Moderna, Inc. (NASDAQ: MRNA) Investment Insights

Core Insights - Moderna, Inc. (NASDAQ: MRNA) is recognized for its mRNA technology, which was pivotal in the development of COVID-19 vaccines, and competes with major pharmaceutical companies like Pfizer and BioNTech [1] - Jefferies has set a price target of $30 for Moderna, indicating a modest potential increase of 1.28% from its current price of $29.62 [1][5] Investment Activity - Amundi has reduced its stake in Moderna by 31.9%, selling 425,861 shares, leaving it with 909,429 shares valued at $27.5 million, which is about 0.23% of Moderna [2] - In contrast, Natixis Advisors LLC increased its stake by 70.7%, now holding 17,761 shares valued at $504,000 [2] - Charles Schwab Investment Management Inc. expanded its position in Moderna by 12.2%, owning 2,629,865 shares worth $74.6 million [3] Stock Performance - Despite the varying investment strategies, Moderna's stock price has seen a 2.03% increase, reaching $29.62 [3][5] - The stock has fluctuated between $28.87 and $29.66 today, with a 52-week high of $48.92 and a low of $22.28 [4] - Moderna's market capitalization is approximately $11.57 billion, with a trading volume of 7,159,436 shares on the NASDAQ exchange [4][5]